An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
ImmunoGen, Inc. has announced the approval of grants of non-qualified stock options and restricted stock units (RSUs) under the Inducement Equity Incentive Plan to a new employee. The options have exercise prices of $14.86 per share and will vest over time based on the employee's continued employment.
Positive
None.
Negative
None.
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of October 31, 2023, grants of non-qualified stock options to purchase 2,650 shares of its common stock and restricted stock units (“RSUs”) covering 1,800 shares of its common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to a new employee.
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The options have exercise prices of $14.86 per share, which is equal to the closing price of ImmunoGen’s common stock on the Nasdaq Global Select Market on October 31, 2023. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the grant date and as to an additional 6.25% of the shares underlying the option quarterly thereafter, subject to the employee’s continued employment on each vesting date. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to the employee’s continued employment on each vesting date. Each option and RSU is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option agreement and an RSU agreement covering the respective grants.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
ImmunoGen, Inc. announced the approval of grants of non-qualified stock options and restricted stock units (RSUs) to a new employee.
What is the Inducement Equity Incentive Plan?
The Inducement Equity Incentive Plan is used for granting equity awards to individuals who were not previously employees of ImmunoGen.
What is the exercise price of the options?
The options have an exercise price of $14.86 per share.
How will the options vest?
The options will vest as to 25% of the shares underlying each option on the first anniversary of the grant date and as to an additional 6.25% quarterly thereafter, subject to the employee's continued employment.
How will the RSUs vest?
The RSUs will vest as to 25% of the shares underlying the award on the first anniversary of the grant date and as to an additional 25% annually thereafter, subject to the employee's continued employment.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
